I help life sciences companies with licensing, partnering and other technology based transactions.

Passions

Spending time with family

Experience

Shoreline Enters Partnership with Kite

Cooley advised Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, in its strategic partnership with Kite, a Gilead Company (Nasdaq: GILD) to develop novel cell therapies across a variety of cancer targets. Under the terms of the agreement, Shoreline will receive an upfront payment and will be eligible to receive additional payments totaling over $2.3 billion as well as royalties based on achievement of certain development and commercial milestones.

Read more

Related contacts

Charity Williams
Partner, San Diego
Brendan Haberle
Associate, San Diego
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Shoreline Enters Collaboration with BeiGene

Cooley advised Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases,  in its  exclusive worldwide strategic collaboration with BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a global biotechnology company, to develop and commercialize a portfolio of NK-based cell therapeutics with Shoreline’s iPSC NK cell technology and BeiGene’s research and clinical development capabilities for different malignancies. Under the terms of the agreement, Shoreline will receive an upfront cash payment of $45 million from BeiGene and will be eligible to receive additional R&D funding, milestone payments and royalties based upon the achievement of certain development, regulatory, and commercial milestones.  In connection with the agreement, BeiGene has an option to acquire an equity stake in Shoreline in its next round of equity financing, subject to specified conditions.

Read more

Related contacts

Charity Williams
Partner, San Diego
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Versartis $145 Million IPO

March 31, 2014

Palo Alto, Calif. – Cooley advised Versartis on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the Nasdaq Global Stock Market under the symbol "VSAR."

Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.

Related contacts

Barbara Kosacz
Senior Counsel, Palo Alto
Kenneth Guernsey
Senior Counsel , San Francisco
Siana Lowrey
Partner, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Michael Tuscan
Partner, Washington, DC
Fraser Brown
Partner, Washington, DC
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Adamas Pharmaceuticals Initial Public Offering

April 30, 2014

San Francisco – Cooley advised Adamas Pharmaceuticals on its initial public offering. Adamas, a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system, now trades on the Nasdaq Global Stock Market under the symbol "ADMS."

Thus far in 2014, Cooley has advised on 43 completed public offerings, including 22 completed IPOs.

Related contacts

Kenneth Guernsey
Senior Counsel , San Francisco
Danielle Naftulin
Partner, Palo Alto
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Michael Tuscan
Partner, Washington, DC
Fraser Brown
Partner, Washington, DC
Lila Hope
Partner, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Jennifer Raab
Partner, Palo Alto

Related Practices & Industries

Atara – $63 Million IPO and Follow-On Offerings

November 6, 2014

Cooley advised Atara Biotherapeutics on its $63 million initial public offering, $74 million follow-on offering and $207 million follow-on offering.

Atara is a clinical stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company now trades on the Nasdaq Global Market under the symbol "ATRA."

Related contacts

Kenneth Guernsey
Senior Counsel , San Francisco
Jodie Bourdet
Partner, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Bill Christiansen
Partner, Seattle
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

View more